ESC 2024 - Deepak Bhatt gives an overview of the kidney results from the EMPACT-MI trial among patients with acute MI. “What we found in fact was quite reassuring, there was no excess of adverse kidney events with empagliflozin versus placebo”, says Deepak Bhatt.
Effects of empaglifozin on kidney outcomes after acute MI
Share
Save
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Overview
Educational information
This video was recorded during the ESC Congress 2024 in London, UK.
Faculty
Deepak Bhatt, MD is Director of Mount Sinai Heart, New York, NY, US. He also serves as the first-ever Dr. Valentin Fuster Professor of Cardiovascular Medicine.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 11 September 2024
Recommended
Details
Presenters
Overview
ESC 2024 - Deepak Bhatt gives an overview of the kidney results from the EMPACT-MI trial among patients with acute MI. “What we found in fact was quite reassuring, there was no excess of adverse kidney events with empagliflozin versus placebo”, says Deepak Bhatt.
Educational information
This video was recorded during the ESC Congress 2024 in London, UK.
Faculty
Deepak Bhatt, MD is Director of Mount Sinai Heart, New York, NY, US. He also serves as the first-ever Dr. Valentin Fuster Professor of Cardiovascular Medicine.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 11 September 2024
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?